Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Cancer immunotherapy has been revolutionized by targeting specific immune subsets within the tumor microenvironment, where T cells play a pivotal role. Gene-engineered T cell strategies and immune ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells-;a type of cancer immunotherapy-;that can be switched on to varying degrees of intensity and then ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...